[영어] - [한영]

등록자 : 관리자

업데이트 : 2020. 5. 31. 오전 7:10:05

2000원2507

In addition, the Korean Intellectual Property Tribunal (see Decision No. 2000 WON 2507) stated the following:

"Claim 16 of the present application relates to a cerebral activator comprising an anhydrous crystal of pyrrolidinyl acetamide derivatives of general formula I as an effective component. Although the detailed description of the invention does not describe the pharmacological effects, effective amount and administration method, it can be understood from the specification that the pyrrolidinyl acetamide derivatives of general formula I is well-known as a cerebral activator, and the present invention claims a compound which is different from the compound of general formula I only in terms of the crystalline form. Even though the crystalline form of the present invention is different, it is not considered that the pharmacological effects as a cerebral activator, the effective amount and the adminstration method according to the present invention are different from well-known crystalline forms. Accordingly, since it is not necessarily required to describe the pharmacological effects and the like in the detailed description, the original decision that claim 16 of the present application is not supported by the detailed description because it does not describe the pharmacological effects, effective amount and administration method, is wrong."